LOCAL INTRA-BODY DELIVERY SYSTEM

• US 20100063384A1
• Filed: 11/14/2007
• Published: 03/11/2010
• Est. Priority Date: 11/15/2006
• Status: Abandoned Application

• Current Assignee: Navotek Medical Ltd.
• Original Assignee: Navotek Medical Ltd.
• Inventors: Neustadter, David M., Stokar, Saul, Kornblau, Giora, Shchory, Tal
• Application Number:
  US12/312,504
• Publication Number:
  US 20100063384A1
• Time in Patent Office: Days
• US Class Current: 600/424
• CPC Class Codes: A61B 1/00156 using self propulsion
• CPC Class Codes: A61B 2090/392 Radioactive markers
• CPC Class Codes: A61B 5/02755 Radioactive tracers
• CPC Class Codes: A61B 5/065 Determining position of the probe employing exclusively positioning means located on or in the probe, e.g. using position sensors arranged on the probe
• CPC Class Codes: A61B 5/073 Intestinal transmitters
• CPC Class Codes: A61B 6/4057 by using radiation sources located in the interior of the body A61B6/037 takes precedence
• CPC Class Codes: A61B 6/507 for determination of haemodynamic parameters, e.g. perfusion CT
• CPC Class Codes: A61M 31/007 Injectors for solid bodies, e.g. suppositories

Abstract

A system for delivery of a capsule to a target location within a subject body including a capsule including a locomotion element and a gamma emitting radioactive source, a radiation tracking subsystem capable of locating the gamma emitting radioactive source in three dimensions, and a locomotion control subsystem capable of controlling movement of the capsule by effecting movement of the locomotion element, based, at least partly, on a location of the gamma emitting radioactive source provided by the radiation tracking subsystem. A method of measuring a velocity of flow of a fluid at a target location within a subject body including inserting a capsule including a locomotion element and a gamma emitting radioactive source into the body, using a radiation tracking subsystem to locate the gamma emitting radioactive source in three dimensions, moving the capsule to the target location within the body using a locomotion control subsystem which controls movement of the capsule by effecting movement of the locomotion element, based, at least partly, on location of the gamma emitting radioactive source provided by the radiation tracking subsystem, and measuring the velocity of flow of the fluid at the target location. Related apparatus and methods are also described.

Claims

1. A system for delivery of a capsule (9) to a target location within a subject body comprising:

a capsule, of a size less than 3 mm in length and less than 1 mm in diameter, comprising a locomotion element (13) and a gamma emitting radioactive source (12);

a real-time radioactive-radiation tracking subsystem (3) capable of locating the gamma emitting radioactive source (12) in three dimensions; and

a locomotion control subsystem (2) capable of controlling movement of the capsule (9) in real-time by effecting movement of the locomotion element (13), based, at least partly, on a location of the gamma emitting radioactive source (12) provided in real-time by the radiation tracking subsystem (3).

2. The system of claim 1 in which the locomotion control subsystem (2) is configured to use location information from the radiation tracking subsystem (3) to automatically control movement of the capsule (9) to the target location.

4. The system of claim 1 in which the locomotion control subsystem (2) controls movement of the capsule (9) to the target location based, at least partly, on a three dimensional angiographic dataset.

5. The system of claim 4 and further comprising an optical tracker (10) capable of monitoring the subject body and providing data for converting coordinates provided by the radiation tracking subsystem (3) to coordinates provided by the three dimensional angiographic dataset.

6. The system of claim 1 in which the radioactive source (12) emits gamma rays, the source (12) having an activity between 0.001 mCi and 0.5 mCi.

7. The system of claim 1 in which the gamma emitting radioactive source (12) occupies less than 10% of the capsule'"'"'s (9) volume.

8. The system of claim 1 in which the locomotion element (13) in the capsule (9) comprises a magnetic material and the locomotion control subsystem (2) comprises a magnetic field configured to apply to the magnetic material in the capsule at least one member of the group consisting of a force and a torque.

12. The system of any one of the preceding claims and further comprising a substance delivery mechanism comprising a substance to be delivered and a release mechanism configured for releasing the substance.

14. The system of claim 12 and further configured to measure velocity of flow at the target location by releasing the substance at the target location and measuring dispersal of the substance at the target location, wherein the substance is radioactive, and the radiation tracking subsystem is configured:

to measure dispersal of the radioactive substance;

to measure a time taken for the radioactive substance to disperse; and

to calculate the velocity of flow based, at least partly, on the time and the dispersal.

16. The system of claim 14 and further configured to measure impedance at the capsule (9), at two or more different times after the release of the substance, and configured to calculate the velocity of flow based, at least partly, on the measured impedances and the times the impedances were measured.

18. The system of claim 12 in which the substance delivery mechanism comprises a tube which is connected to the capsule (9) through which a substance is delivered to the location of the capsule (9).

19. The system of claim 1 in which the locomotion control subsystem (2) includes a tether connected to the capsule (9).

23. The system of claim 19 in which the tether comprises at least one wire capable of conducting electrical current.

24. The system of claim 1 and wherein the system is configured to deliver the capsule (9) to the target location through one or more blood vessels.

26. The system of claim 24 in which the capsule (9) is configured to receive locomotion from blood flow and the locomotion control subsystem (2) is configured to provide steering to the capsule (9).

60. The system of claim 1 in which the capsule (9) is of a size suitable for being injected into a body by a needle.

3. (canceled)

9-11. -11. (canceled)

13. (canceled)

15. (canceled)

17. (canceled)

20-22. -22. (canceled)

25. (canceled)

27-29. -29. (canceled)

30. A method of delivering a capsule (9) to a target location within a subject body comprising:

inserting a capsule (9), of a size less than 3 mm in length and less than 1 mm in diameter, comprising a locomotion element (13) and a gamma emitting radioactive source (12) into the body;

using a real-time radioactive-radiation tracking subsystem (3) to locate the gamma emitting radioactive source (12) in three dimensions; and

moving the capsule (9) to the target location within the body using a locomotion control subsystem (2) to control movement of the capsule (9) in real-time by effecting movement of the locomotion element (13), based, at least partly, on location of the gamma emitting radioactive source (12) provided in real-time by the radiation tracking subsystem (3).

31. The method of claim 30 in which the locomotion control subsystem (2) uses location information from the radiation tracking subsystem (3) to automatically control movement of the capsule (9) to the target location.

33. The method of claim 30 in which the locomotion control subsystem (3) controls movement of the capsule (9) to the target location based, at least partly, on a three dimensional angiographic dataset.

34. The method of claim 33 and further comprising an optical tracker (10) capable of monitoring the subject body and providing data for converting coordinates provided by the radiation tracking subsystem (3) to coordinates provided by the three dimensional angiographic dataset.

35. The method of claim 30 in which the radioactive source (12) emits gamma rays with an activity between 0.001 mCi and 0.5 mCi.

36. The method of claim 30 in which the gamma emitting radioactive source (12) occupies less than 10% of the capsule'"'"'s (9) volume.

37. The method of claim 30 and further releasing a substance from the capsule (9) into the body.

39. The method of 38claim 30 in which the moving the capsule (9) is performed through one or more blood vessels.

44. The method of claim 30 in which the capsule (9) is connected to an electric wire and the moving the capsule (9) to the target location brings the end of the electric wire connected to the capsule to the target location.

32. (canceled)

38. (canceled)

40-43. -43. (canceled)

45. A method of measuring a velocity of flow of a fluid at a target location within a subject body comprising:

inserting a capsule (9) comprising a locomotion element (13) and a gamma emitting radioactive source (12) into the body;

using a real-time radioactive-radiation tracking subsystem (3) to locate the gamma emitting radioactive source (12) in three dimensions;

moving the capsule (9) to the target location within the body using a locomotion control subsystem (2) which controls movement of the capsule (9) in real-time by effecting movement of the locomotion element (13), based, at least partly, on location of the gamma emitting radioactive source (12) provided in real-time by the radiation tracking subsystem (3); and

measuring the velocity of flow of the fluid at the target location.

46. The method of claim 45 and further comprising, after the moving the capsule (9), releasing a therapeutic substance at the target location.

47. The method of claim 45 in which the locomotion control subsystem (2) uses location information from the radiation tracking subsystem (3) to automatically control movement of the capsule (9) to the target location.

49. The method of claim 45 in which the locomotion control subsystem (2) controls movement of the capsule (9) to the target location based, at least partly, on a three dimensional angiographic dataset.

50. The method of claim 49 and further comprising an optical tracker (10) capable of monitoring the subject body and providing data for translating coordinates provided by the radiation tracking subsystem (3) to coordinates provided by the three dimensional angiographic dataset.

51. The method of claim 45 in which the radioactive source (12) emits gamma rays with an activity between 0.001 mCi and 0.5 mCi.

52. The method of claim 45 and further:

releasing a radioactive substance from the capsule (9) into the fluid;

using the radiation tracking subsystem (3) to measure dispersal of the radioactive substance;

measuring a time taken for the radioactive substance to disperse; and

calculating a velocity of flow based, at least partly, on the time and the dispersal.

53. The method of claim 45 and further:

releasing a substance from the capsule (9) into the fluid;

measuring changes in impedance at the capsule (9), at two or more different times after the release of the substance; and

calculating a velocity of flow based, at least partly, on the measuring of the changes in impedance and on the times the changes in impedance were measured.

54. The method of claim 45 and further:

releasing a substance from the capsule (9) into the fluid;

measuring changes in temperature at the capsule (9), at two or more different times after the release of the substance; and

calculating a velocity of flow based, at least partly, on the measuring of the changes in temperature and on the times the changes in temperature were measured.

55. The method of claim 45 in which the moving the capsule (9) is performed through one or more blood vessels.

48. (canceled)

56-59. -59. (canceled)